tetano
Editor, Senior Moderator
Intern Med
. 2022 Mar 26.
doi: 10.2169/internalmedicine.8967-21. Online ahead of print.
Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination
Shunsuke Ogata[SUP] 1 [/SUP], Yoshito Ishi[SUP] 1 [/SUP], Keiichiro Asano[SUP] 1 [/SUP], Erena Kobayashi[SUP] 1 [/SUP], Shun Kubota[SUP] 1 [/SUP], Keita Takahashi[SUP] 1 [/SUP], Yosuke Miyaji[SUP] 1 [/SUP], Yuichi Higashiyama[SUP] 1 [/SUP], Hideto Joki[SUP] 1 [/SUP], Hiroshi Doi[SUP] 1 [/SUP], Michiaki Koga[SUP] 2 [/SUP], Hideyuki Takeuchi[SUP] 1 [/SUP], Fumiaki Tanaka[SUP] 1 [/SUP]
Affiliations
Abstract
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Keywords: COVID-19; Guillain-Barré syndrome; dysgeusia; sensory ataxia; vaccination.
. 2022 Mar 26.
doi: 10.2169/internalmedicine.8967-21. Online ahead of print.
Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination
Shunsuke Ogata[SUP] 1 [/SUP], Yoshito Ishi[SUP] 1 [/SUP], Keiichiro Asano[SUP] 1 [/SUP], Erena Kobayashi[SUP] 1 [/SUP], Shun Kubota[SUP] 1 [/SUP], Keita Takahashi[SUP] 1 [/SUP], Yosuke Miyaji[SUP] 1 [/SUP], Yuichi Higashiyama[SUP] 1 [/SUP], Hideto Joki[SUP] 1 [/SUP], Hiroshi Doi[SUP] 1 [/SUP], Michiaki Koga[SUP] 2 [/SUP], Hideyuki Takeuchi[SUP] 1 [/SUP], Fumiaki Tanaka[SUP] 1 [/SUP]
Affiliations
- PMID: 35342134
- DOI: 10.2169/internalmedicine.8967-21
Abstract
Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Keywords: COVID-19; Guillain-Barré syndrome; dysgeusia; sensory ataxia; vaccination.